158 related articles for article (PubMed ID: 38720336)
1. Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer.
Liu Y; Chen W; Ruan R; Zhang Z; Wang Z; Guan T; Lin Q; Tang W; Deng J; Wang Z; Li G
J Transl Med; 2024 May; 22(1):438. PubMed ID: 38720336
[TBL] [Abstract][Full Text] [Related]
2. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.
Han Z; Zhang Z; Yang X; Li Z; Sang S; Islam MT; Guo AA; Li Z; Wang X; Wang J; Zhang T; Sun Z; Yu L; Wang W; Xiong W; Li G; Jiang Y
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38749538
[TBL] [Abstract][Full Text] [Related]
3. Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer.
Zhou Z; Ren Y; Zhang Z; Guan T; Wang Z; Chen W; Luo T; Li G
Gastric Cancer; 2023 Sep; 26(5):734-742. PubMed ID: 37322381
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
Li LH; Chen WC; Wu G
Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
8. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
9. Deep learning-based subtyping of gastric cancer histology predicts clinical outcome: a multi-institutional retrospective study.
Veldhuizen GP; Röcken C; Behrens HM; Cifci D; Muti HS; Yoshikawa T; Arai T; Oshima T; Tan P; Ebert MP; Pearson AT; Calderaro J; Grabsch HI; Kather JN
Gastric Cancer; 2023 Sep; 26(5):708-720. PubMed ID: 37269416
[TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
11. Prediction of genetic alterations from gastric cancer histopathology images using a fully automated deep learning approach.
Jang HJ; Lee A; Kang J; Song IH; Lee SH
World J Gastroenterol; 2021 Nov; 27(44):7687-7704. PubMed ID: 34908807
[TBL] [Abstract][Full Text] [Related]
12. Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors.
Formica V; Morelli C; Patrikidou A; Murias C; Butt S; Nardecchia A; Lucchetti J; Renzi N; Shiu KK; Roselli M; Arkenau HT
Target Oncol; 2020 Jun; 15(3):327-336. PubMed ID: 32449030
[TBL] [Abstract][Full Text] [Related]
13. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
16. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.
Tang X; Li M; Wu X; Guo T; Zhang L; Tang L; Jia F; Hu Y; Zhang Y; Xing X; Shan F; Gao X; Li Z
Oncoimmunology; 2022; 11(1):2135819. PubMed ID: 36268179
[TBL] [Abstract][Full Text] [Related]
18. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
19. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
20. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]